P.P. Schiphorst

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer et al. · The Lancet Oncology · 2017 · 157 citations

Medicine, Clinical Trials, Gynecology +10

Vaccination of Melanoma Patients with an Allogeneic, Genetically Modified Interleukin 2-Producing Melanoma Cell Line

Susanne Osanto, P.P. Schiphorst, Nir I. Weijl et al. · Human Gene Therapy · 2000 · 76 citations

Vaccination, Cancer Immunosurveillance, Allergy +15

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 36 citations · Full text

Neoadjuvant Chemotherapy Duration, Breast Oncology, Medical Imaging +10

Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer

P.P. Schiphorst, Pei-Jen Chang, N. Clar et al. · Annals of Oncology · 1999 · 13 citations

Anephric Patients, Medicine, Immunology +7

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

Mark Opdam, Vincent van der Noort, Miranda Kleijn et al. · Breast Cancer Research and Treatment · 2022 · 13 citations · Full text